Elevated Epstein–Barr virus loads and lower antibody titers in competitive athletes
✍ Scribed by Dieter Hoffmann; Bernd Wolfarth; Hubert G. Hörterer; Martin Halle; Christine Reichhuber; Korinna Nadas; Catrin Tora; Volker Erfle; Ulrike Protzer; Hermann M. Schätzl
- Book ID
- 102382988
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 118 KB
- Volume
- 82
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Epstein–Barr virus (EBV) is a persisting herpesvirus which is controlled by the adaptive immune response after primary infection and maintained in a latent state. However, reactivation or persistent replication is observed in situations where the immune response is compromised. Since intensive physical training has been reported to diminish immune function, increased EBV load may be a cause of reduced performance and decreased ability to sustain high training loads in competitive athletes. Samples drawn from 209 athletes during their regular follow‐up appointments were tested. One hundred sixty‐five individuals of similar age not active in competitive sports served as case–controls. EBV load was quantified in peripheral blood leucocytes (PBLs) by real‐time PCR, and EBV antibodies were detected in plasma by ELISA and immunoblot analysis. EBV DNA was detectable in 25 of 209 athletes and in 26 of 165 controls. Of note, the EBV load per 10^5^ PBLs was 6.44 ± 1.75 in the case and 1.67 ± 0.44 copies in the controls, yielding a high significant difference (P < 0.0001). However, EBV‐specific IgG titers were significantly lower in athletes (150.4 ± 10.73 U ml^−1^ vs. 241.6 ± 18.59 U ml^−1^). As monitored by immunoblotting, primary infections were detected with low prevalence, three in the case group and one in the control group. These findings demonstrate that EBV is present at higher levels in athletes, but the antibody response is lower in athletes than in the controls. J. Med. Virol. 82:446–451, 2010. © 2010 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Epstein-Barr virus (EBV) has recently been identified in the tumor cells of patients with gastric carcinoma. We tested pre-morbid serum samples from a carefully monitored cohort of Japanese men in order to investigate the possibility that patients with EBV-associated gastric cancer represent a sub-s
## Abstract Seven American juvenile patients with undifferentiated or nonkeratinizing nasopharyngeal carcinoma (NPC) were examined serially for Epstein‐Barr virus (EBV)‐specific antibody spectra and titers in sera. At diagnosis, all showed antibody patterns characteristic of NPC: __i.e.__, high tit